For verified healthcare professionals
Log in or register for free to read this article. HPN is for healthcare professionals, so new accounts are verified by our team.
Targeted Radionuclide therapy in advanced prostate cancer
Radionuclide therapy has been important in the treatment of metastatic prostate cancer for over 30 years, and a recently approved therapy, Lutetium-177- PSMA-617 (PLUVITCO ™, Novartis) has heralded a new and exciting era for the field.
